374 related articles for article (PubMed ID: 27626176)
41. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
42. Interventional treatment for unresectable hepatocellular carcinoma.
Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
[TBL] [Abstract][Full Text] [Related]
43. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
44. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
45. [Therapy of hepatocellular carcinoma].
Wörns MA; Klöckner R; Weinmann A; Galle PR
Internist (Berl); 2014 Jan; 55(1):23-4, 26-30. PubMed ID: 24240604
[TBL] [Abstract][Full Text] [Related]
46. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
47. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
Gerbes A; Zoulim F; Tilg H; Dufour JF; Bruix J; Paradis V; Salem R; Peck-Radosavljevic M; Galle PR; Greten TF; Nault JC; Avila MA
Gut; 2018 Feb; 67(2):380-388. PubMed ID: 29150490
[TBL] [Abstract][Full Text] [Related]
48. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
Yaghmai V; Besa C; Kim E; Gatlin JL; Siddiqui NA; Taouli B
AJR Am J Roentgenol; 2013 Jul; 201(1):80-96. PubMed ID: 23789661
[TBL] [Abstract][Full Text] [Related]
49. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
50. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
51. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma.
Peng ZW; Chen MS
Oncology; 2013; 84 Suppl 1():40-3. PubMed ID: 23428857
[TBL] [Abstract][Full Text] [Related]
52. Systemic therapies for hepatocellular carcinoma.
Ge S; Huang D
Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544
[TBL] [Abstract][Full Text] [Related]
53. Chemoembolization and bland embolization: a critical appraisal.
Befeler AS
Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
[TBL] [Abstract][Full Text] [Related]
54. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.
Liu TH; Shao YY; Lu LC; Shen YC; Hsu C; Lin ZZ; Hsu CH; Cheng AL
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):615-621. PubMed ID: 31132887
[No Abstract] [Full Text] [Related]
55. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
Brown ZJ; Hewitt DB; Pawlik TM
Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
[TBL] [Abstract][Full Text] [Related]
56. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
57. Updated treatment approach to hepatocellular carcinoma.
Llovet JM
J Gastroenterol; 2005 Mar; 40(3):225-35. PubMed ID: 15830281
[TBL] [Abstract][Full Text] [Related]
58. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Yarchoan M; Agarwal P; Villanueva A; Rao S; Dawson LA; Llovet JM; Finn RS; Groopman JD; El-Serag HB; Monga SP; Wang XW; Karin M; Schwartz RE; Tanabe KK; Roberts LR; Gunaratne PH; Tsung A; Brown KA; Lawrence TS; Salem R; Singal AG; Kim AK; Rabiee A; Resar L; Hoshida Y; He AR; Ghoshal K; Ryan PB; Jaffee EM; Guha C; Mishra L; Coleman CN; Ahmed MM
Cancer Res; 2019 Sep; 79(17):4326-4330. PubMed ID: 31481419
[TBL] [Abstract][Full Text] [Related]
59. Multidisciplinary management of hepatocellular carcinoma: where are we today?
Marrero JA
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S3-10. PubMed ID: 23457037
[TBL] [Abstract][Full Text] [Related]
60. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
Zhou H; Song T
Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
